reason report
thv upsid adopt inflect sustain still unclear us
bottom line ew report adjust sale y/i
ex fx -- predict quarterli tavr transcathet
aortic valv replac survey -- meaning beat us
consensu primarili driven thv transcathet heart valv
clearli ew benefit least temporari inflect bolu per
manag medacorp physician check miss base
recent survey check point low-to-mid teen procedur
volum growth link manag commentari around
expect return low double-digit tavr procedur volum growth
remain cautiou durabl inflect
believ ew like conserv growth commentari
effort manag expect ahead provid offici guidanc
analyst meet survey medacorp physician
convers also necessarili point upsid would
give us comfort much upsid current mid-teen
consensu growth project ew global thv sale ew
med-tech share trade meaning premium
group think littl room error ew
continu deliv consist beat rais go
forward -- someth limit confid base
aforement medacorp physician check survey street
estim inevit move higher tomorrow ew share --
undoubtedli deserv -- mind also reset
bar higher go forward continu believ ew
strong like unfalt market-lead posit one higher-
growth attract market within med-tech share trade
price-to-earnings estim remain sidelin pend
increas level confid inflect sustain
reiter mp pt price target --
previous -- appli price-to-earnings multipl ep estim
pt assum stabl multipl current ep
estim well large-cap group averag
think ew market-lead posit highli
valuat rel rest large-cap med-tech group mp
op mp op mp op op
think premium seem unlik thu would
reli sole estim upsid push pt meaning higher
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil ew
compani inform svb leerink llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
sale estim move higher boost tavr
out-performance bolu manag cite call fall
well gener higher tavr market growth outlook
sale estim y/i
previous ep also move
higher period larg driven now-high top-lin lower
tax rate
takeaway call beyond thv out-performance
investor could also focu bit lighter mitral quarter think
investor expect come --
ytd -- prompt manag lower guidanc
vs previous given mitral next leg
growth ew stori investor disproportion focus
busi rel overal import sale current though thv
out-performance like overshadow perceiv mitral shortcom
ew also push early-tavr enrol timelin
-- expect complet trial
enrol recal clinic trial studi tavr asymptomat
aortic stenosi patient ew past state make half
total sever aortic stenosi patient popul
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul intermedi low risk occur
slower pace already-elev investor expect continu believ
intermedi risk -- low risk -- indic repres massiv increment market
opportun also believ ramp patient slower saw
inoper high risk low risk ramp like even slower seen
term need seemingli intens market develop effort drive referr
move risk curv particularli younger less sick portion intermedi
risk patient popul low risk patient popul potenti increas surgeon
pushback less sick patient popul heart member ramp effort
preserv surgic busi
near-to-medium term ew still beat rais stori share current trade
earn becom increasingli difficult argu meaning multipl
expans
price target appli price-to-earnings multipl ep estim
pt assum stabl multipl current ep estim
large-cap group averag also think ew market-lead posit
highli under-penetrated total address market justifi premium valuat rel
rest large-cap med-tech group mp op mp op
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid therapi
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
sg sale sale
neg impact
top
top
impact
impact
impact
high end
high end
high end
high end
top
higher end
higher end
higher end
higher end
around top
around top
top end
top end
sale tmtt
includ
tmtt
tmtt
tmtt
ew initi trial low-risk patient earli enrol trial began
random trail studi sapien low risk patient enrol
expect continu risk defin patient st score ew
see next step expans market intermedi risk posit trial
enrol year age limit also remov protocol
 oct trial tooker littl longer start-up phase ew continu expect earn call
site engag
 octob compani expect enrol complet year end
 decemb main studi enrol complet ct sub-studi continu enrol
 april ew receiv approv limit continu access protocol cap allow on-going
treatment select clinic site limit number low-risk patient sapien
approv cap continu access protocol cap program allow treatment complet trial
 juli ew still expect begin program
all-caus mortal stroke re-hospit time frame year post procedur
composit endpoint evalu non-inferior analysi base rel non-inferior margin
 februari ew expect result present
 decemb ew expect fda approv late
clinic trial prospect random control multi-cent studi patient
random receiv either transcathet aortic valv replac tavr edward
sapien thv clinic surveil patient stratifi whether abl
perform treadmil stress test patient posit stress test follow registri
collect data subsequ treatment mortal applic
ew plan enrol patient year older
 januari receiv fda approv patient across center begin enrol later
 octob trial continu enrol
 decemb analyst day patient enrol date ew expect complet enrol
 octob trial half enrol ew expect complet enrol
sapien ultra new deliveri system expect better command system
new ultra system featur on-balloon deliveri system nextgener sheath technolog
sapien pulmon
 sapien pulmon valv expand indic pulmnic rvot conduit patch patient
 alterra adapt prestent pulmon patch patient expand treatabl popul
resili trial evalu
durabl aortic
resilia tissu subject
object observ trial determin time valv failur due valv deterior
requir re-intervent collect/investig earli potenti predictor valv durabl
calcif hemodynam deterior resilia tissu valv
-a decemb ew expect new ultra system featur on-balloon deliveri system nextgener
sheath technolog receiv ce mark end earli launch
 april ew conduct small clinic trial sapien ultra system supplement european regulatori
submiss unanticip start process reflect evolv european regulatori climat
manag expect complet enrol patient quarter receiv ce mark approv ultra system
second half
 juli enrol still on-going ew still expect secur ce mark
 octob ew still expect secur ce mark
 receiv ce mark novemb
 decemb compani expect approv late
 juli ew still expect fda approv late
 decemb ew expect fda approv end
 decemb pivot trial plane
end
multicent prospect non-random single-arm observ trial subject evalu year
post-impl two hundr fifti total subject fifteen investig site enrol
primari outcom measur time bioprosthet valv failur due valv deterior time frame year post-impl
-a januari ew recent paus enrol clinic trial perform design valid test featur
valv ew see posit result test clinic trial expect resum enrol paus
also postpon start ce mark trial
 juli ew expect resum enrol year
 octob ew decid includ number signific enhanc valv serv broader
group patient
 decemb expect enrol resum enhanc made
octob ew decid commerci valv system incorpor number enhanc ew
current ce mark expect
 decemb slimmer devic profil new transsapi deliveri system expect introduc
ew plan enrol multi-cent prospect single-arm non-random studi
-a plan enrol patient
ce mark studi subject complet document reduct sever mitral
regurgit mr improv minut walk test subject moder sever mr ew
aleadi ce mark product europ commerci launch on-go
 record commer sale europ
 present year follow-up data tct
cardioband repair studi transcathet repair mitral insuffici cardioband system
repair cardioband transcathet cardioband indic treatment
secondari function mitral regurgit fmr cardioband transcathet system deploy
beat heart transsept approach cardioband deploy along posterior
annulu mitral valv mv adjust trans-esophag guidanc beat heart
studi object test efficaci cardioband improv mr heart failur symptom
patient symptomat new york heart associ nyha class iii-iva sever mr post-
market set evalu safeti cardioband system post-market set
 pivot trial activ trial prospect random multicent trial patient
clinic signific function mitral regurgit random receiv either transcathet
mitral valv repair edward cardioband system plu guidelin direct medic therapi
gdmt gdmt alon patient seen follow-up visit discharg day month
annual year
complet enrol complet may ew actual enrol patient vs patient anticip
reduct sever mr day least one categori scale time frame day
on-go ew plan enrol patient
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
complet decemb publish posit data lancet present month result tct
ew plan enrol patient earli feasibl studi
 octob ew begun enrol ce mark trial expect expand trial multipl center
remaind year
 februari ew expect complet enrol
 decemb expect product launch
 decemb expect product launch
 februari ew track initi pascal trial
 juli ew continu treat patient feasibl studi
ew plan enrol patient
 juli studi statu chang activ recruit recruit
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
composit major advers event mae defin cardiovascular mortal stroke myocardi infarct new need renal
replac therapi sever bleed re-intervent studi devic relat complic day time frame
primari endpoint assess day
 octob ew receiv fda approv initi pascal pivot trial
on-go ew plan enrol patient
clasp iid prospect multicent random control pivot trial evalu safeti
effect transcathet mitral valv repair edward pascal transcathet mitral
valv repair system compar abbott mitraclip patient degen mitral regurgit
pascal inferior mitraclip respect proport patient major advers event mae primari
safeti endpoint composit major advers event mae time frame day
pascal inferior mitraclip respect proport patient mr sever reduct measur
echocardiographi use scale time frame month
cardioband activ enrol ce mark trial expand indic tricuspid patient target
ce mark approv
 earli feasibl studi set start
studi multi-cent prospect single-arm non-random studi design evalu
safeti perform edward cardioband tricuspid valv reconstruct system
 decemb ew plan initi pivot trial late
complet juli ew complet enrol ce mark trial cardioband tricuspid physician
 patient day earli readout present tct demonstr high procedur success good safeti
 decemb expect eu introduct late
 juli ew receiv ce mark
 februari ew receiv approv begin earli feasibl studi work activ center
 juli ew track begin earli feasibl studi may limit suppli
ew plan enrol patient
 januari ew increas estim enrol
repair treat broad
spectrum mitral regurgit
cardioband transcathet cardioband market system approv
treatment secondari function mitral regurgit fmr ce grant septemb
cardioband annuloplasti band similar surgic annuloplasti howev deploy
beat heart transven approach ce mark studi subject
complet document signific reduct sever mr improv qualiti life
minnesota live heart failur questionnair mlhfq ney york heart associ nyha
minut walk test subject moder sever mr aim current studi
evalu cardioband annuloplasti system repair tricuspid regurgit
on-go ew plan enrol patient
spacer trial repair
use edward tricuspid
purpos studi assess safeti devic perform edward tricuspid
transcathet repair patient clinic signific symptomat tricuspid regurgit
high surgic risk standard tricuspid repair/replac studi multi-cent
intern prospect singl arm safeti studi enrol subject assess clinic follow-
month month year annual year post implant procedur
primari endpoint studi assess mortal cardiac treat cohort day compar literatur
deriv perform goal base high-risk surgic outcom tricuspid repair/replac
edward announc structur up-front invest harpoon pioneer beating-heart repair
degen mitral regurgit dmr exclus option acquir compani
dec edward announc acquisit harpoon medic inc million cash
potenti million pre-specifi milestone-driven payment next
 decemb ce mark expect year end earli
 april ew learn complic three treat earli clinic studi may influenc
time commerci launch
 februari ew expect european launch
 octob ew provid updat timelin
 juli ew expect european launch
